• The company’s revenue increased by 5.5% over 2023, which at constant exchange rates would represent an increase of 7.2%, driven by growth in all business areas.
• Adjusted EBITDA continues to grow significantly, up 13.8% to €48.5M, and adjusted operating cash flow is up 20.1%.
• The company reduced its negative consolidated result by 31%, which at year-end stood at -31.7M€.

Atrys, a global healthtech company providing precision medical prevention, diagnosis and treatment services, leader in telemedicine and oncology treatment, has announced its results for the 2024 financial year, which reflect organic growth with revenue reaching 212.7 million euros, 5.5% more than in 2023 (7.2% at constant exchange rates), and adjusted EBITDA continuing to grow significantly (13.8%), reaching 48.5 million euros.

Gross margin increased by 2% to 140 million euros, while adjusted operating cash flow grew by 20.1% to 35.3 million euros.

Gross debt for the year is reduced by 4.3% to €191M, and the leverage ratio (net financial debt to EBITDA) is reduced from 3.6x to 3.29x in FY2024.

Santiago de Torres, CEO of Atrys, said, “These results reflect the strength and efficiency of our business model. All of our business lines are performing well in both revenue and EBITDA, demonstrating our ability to generate value in a sustained and profitable manner. Improved EBITDA and reduced leverage provide us with a solid foundation to confidently implement our long-term growth and consolidation strategy”.

Growth in all business areas

Atrys continues to strengthen its growth in its business lines – prevention, diagnostics and oncology – both in Spain and Latin America. Specifically, the company’s turnover in the Spanish market grew by 4% to 156 million euros. In Portugal, turnover amounted to 15 million euros, 7% more than in 2023. In the Latin American market, Atrys’s turnover grew by 11.6% to 42 million euros.

By areas of activity, in the Prevention segment, the area with the greatest weight in turnover, the company achieved a 4.4% increase in revenues, to 82.8 million euros.

Turnover in the Diagnostics segment grew by 3.5% to €66.9M, which at constant exchange rates would represent an increase of 9.2%.

Finally, Atrys’ Oncology division led growth with €63M in revenues, up 9.5% on the same period last year, driven mainly by activity in Mexico.